Dr. Thomas Hutson on Drug Sequencing in Renal Cell Carcinoma

Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncology—Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.

Seven new agents have been approved for renal cell over a relatively short period of time. That has made it difficult to determine which drugs should be used for first, says Hutson.

An evidence-based approach is the best way to determine which drugs will be the most effective in the frontline setting. Sunitinib and pazopanib both have drug evidence from phase III trials demonstrating great efficacy, safety, and tolerability and should be considered for the frontline setting for renal cell.